Srikanth Nadella, MD
Internal Medicine · Maryville, ILNPI 1740599109
Payments from drug & device makers
Across 183 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$806
- Abbott$573
- Lilly USA, LLC$496
- Medtronic$483
- AstraZeneca$352
- Dexcom, Inc.$268
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,073100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $806 |
| Abbott | 31 | $573 |
| Lilly USA, LLC | 24 | $496 |
| Medtronic | 9 | $483 |
| AstraZeneca(2 entities) | 9 | $352 |
| Dexcom, Inc. | 11 | $268 |
| Insulet Corporation | 3 | $176 |
| Mannkind Corporation | 7 | $123 |
| Xeris Pharmaceuticals, Inc. | 6 | $119 |
| Bayer | 6 | $112 |
| Boehringer Ingelheim | 4 | $79 |
| Corcept Therapeutics | 3 | $63 |
| Clarus Therapeutics Inc. | 3 | $53 |
| Tandem Diabetes Care, Inc. | 3 | $53 |
| Amgen | 3 | $50 |
| BETA Bionics, Inc. | 4 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| IBSA Pharma Inc. | 2 | $31 |
| Averitas Pharma Inc. | 1 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| AbbVie | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $17 |
| Merck | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$139
- MINIMED 780G$132
- CALQUENCE$125
- Omnipod$122
- FARXIGA$108
How this compares
$4,073 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $240,320 |
| MounjaroTirzepatide | 105 | $150,222 |
| JardianceEmpagliflozin | 62 | $89,705 |
| FarxigaDapagliflozin Propanediol | 91 | $86,570 |
| TrulicityDulaglutide | 32 | $46,886 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $38,697 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $27,626 |
| RybelsusSemaglutide | 13 | $24,876 |
| Gvoke Hypopen 2-PackGlucagon | 35 | $21,963 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $18,745 |
| JanuviaSitagliptin Phosphate | 20 | $17,736 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $17,649 |
| VascepaIcosapent Ethyl | 15 | $12,316 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 16 | $11,759 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $8,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $806 | $269,516159 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $496 | $201,176152 claims |
| Boehringer IngelheimJardiance | $79 | $89,70562 claims |
| AstraZenecaFarxiga | $352 | $86,57091 claims |
| MerckJanuvia | $15 | $17,73620 claims |
| AbbVieSynthroid | $19 | $2,51024 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $25 | $45292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Maryville
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.